EP0377517A2 — Theophylline dosage form
Assigned to Mayne Pharma International Pty Ltd · Expires 1990-07-11 · 36y expired
What this patent protects
A sustained release pharmaceutical pellet composition suitable for treating cardiotonic, diuretic or respiratory conditions comprises a core element including a theophylline compound, e.g. an ethylene diamine salt of theophylline, and a core coating for the core element which is …
USPTO Abstract
A sustained release pharmaceutical pellet composition suitable for treating cardiotonic, diuretic or respiratory conditions comprises a core element including a theophylline compound, e.g. an ethylene diamine salt of theophylline, and a core coating for the core element which is partially soluble at a highly acidic pH to provide a slow rate of release of theophylline compound and wherein the theophylline compound is available for absorption at a relatively constant faster rate in the intestine over an extended period of time.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.